The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 March 2026•

1 min read

Analysts Forecast Significant Upside for Genpact, Assertio, and OrthoPediatrics

A man in glasses and a turtleneck stands amidst various LG display screens, laptops, transparent panels, and a frequency graph.

Key Facts

1Analysts predict a 25.49% upside for Genpact (G) stock.

2Average price targets for Assertio (ASRT) indicate a potential upside of 182.79%.

Version History

3 additional sources confirmed this story

Wall Street analysts have issued optimistic price targets for Genpact (G), Assertio (ASRT), and OrthoPediatrics (KIDS), signaling significant growth potential. Assertio leads the group with a projected upside of 182.79%, while OrthoPediatrics and Genpact are expected to rise by 51.12% and 25.49%, respectively. These bullish forecasts are largely driven by a consensus among analysts regarding upward revisions in earnings estimates. Such revisions are frequently considered a precursor to actual stock price appreciation in the equity markets. While these targets reflect strong market sentiment, investors should note that they are based on analyst projections and historical trends. The positive outlook underscores a growing confidence in the financial performance and strategic direction of these three companies. This assessment provides a bullish signal for investors monitoring mid-cap and small-cap opportunities in the tech and healthcare sectors.